Tiziana Life Sciences Ltd (NASDAQ:TLSA) chairman and CEO Gabriele Cerrone joined Proactive's Stephen Gunnion with more details of the company's recent advancements and news. Tiziana Life Sciences is developing a fully human CD3 monoclonal antibody, delivered intranasally, specifically targeting neurodegenerative diseases such as multiple sclerosis (MS) and Alzheimer's disease.
Cerrone discussed the company's progress in MS treatments, highlighting its expanded access trial at Harvard University's Brigham and Women's Hospital. Notably, 70% of patients in the trial showed improvement in fatigue scores, while 80% experienced reduced brain inflammation.
The company is also preparing to dose the first Alzheimer's patients in a new trial approved by the FDA.
Furthermore, Tiziana Life Sciences is exploring the combination of its drug with GLP-1 antagonists to target obesity-related diseases.
Cerrone shared the exciting news of securing $3.4 million in non-dilutive funding, emphasising its commitment to protecting shareholder investments.
"We have seen extraordinary improvements in patients, and we are thrilled about the potential impact of our treatments on neurodegenerative diseases," he remarked.
Visit Proactive's KZread channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content.
#TizianaLifeSciences #GabrieleCerrone #MultipleSclerosis #Alzheimers #ClinicalTrials #BiotechNews #MedicalResearch #NeurodegenerativeDiseases #NonDilutiveFunding #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews